You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
ESMO Asia 2024: 和譽醫藥以口頭報吿形式展示其口服PD-L1抑制劑ABSK043的最新1期研究結果
格隆匯 12-06 12:04

格隆匯12月6日丨2024年12月6日,和譽-B(02256.HK)宣佈,其已在於新加坡舉辦的2024年歐洲腫瘤內科學會亞洲年會"ESMO Asia 2024")上以口頭報吿形式展示其自主研發的口服PD-L1抑制劑ABSK043治療晚期實體瘤患者的最新1期研究結果。

研究結果表明,在600mg-1000mg BID劑量組,ABSK043單藥具有良好的安全性和抗腫瘤活性。在PD-L1高表達的非小細胞肺癌("NSCLC")患者中,即使患者存在EGFR或KRAS突變,並曾接受過系統性治療,也能觀察到更顯着的療效。這些發現將持續支持ABSK043在EGFR突變肺癌和各種其他實體瘤中的進一步研究。

和譽醫藥在ESMO Asia 2024上展示:

報吿編號:485

標題:用治療晚期實體瘤患者的口服PD-L1抑制劑ABSK043的1期研究最新結果

報吿時間:2024年12月6日上午10:42至上午10:52

ABSK043是和譽醫藥獨立自主研發並完全擁有的一款全新的具備優異活性及高度選擇性的口服小分子PD-L1抑制劑。腫瘤細胞可以利用PD-1及其配體PD-L1等免疫檢查點來逃避免疫監管和清除,從而抑制或限制T細胞應答。ABSK043可選擇性地與PD-L1受體特異性結合並誘導其從細胞表面內吞,有效地抑制PD-1/PD-L1的相互作用,解除PD-L1介導的T細胞活化抑制作用。ABSK043在多個臨牀前模型中展現出與已獲批PD-L1抗體相當的抗腫瘤功效。迄今為止,全球已有多款PD-1/PD-L1單抗體藥物獲批上市,但並無PD-1/PD-L1口服小分子藥物獲批。目前ABSK043針對晚期實體腫瘤的I期臨牀試驗正在澳大利亞和中國開展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account